| ID | 1089 |
| Name of the vaccine | Tripacel |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 2 months to 6 years |
| Description of the vaccine | Diphtheria, tetanus toxoids and acellular pertussis vaccine adsorbed. |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 1998 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | NA |
| Vaccine formulation | White to off-white suspension for injection |
| Dosage | Four dose series with 3 doses at gap of 2 months, followed by a booster dose 6 to 12 months after the third dose. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus and pertussis. |
| Export | Marketing Authorisation Holder: Sanofi Pasteur Ltd, Bangkok, Thailand |
| Approval | Thailand FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | Also for diphtheria and pertussis. |
| Side effects of vaccine | Drowsiness, injection site tenderness, swelling, redness, fever, irritability, decreased feeding. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.moph.go.th/sites/drug/Summary/2C_18_41_N.pdf |
| Other name | NA |
| Additional Links | NA
|